TRIAL |
NAME |
ACTIVATION
DATE |
CURRENT
STATUS* |
CLOSURE
DATE |
TOTAL
# REGs |
| I1C | AT-125; colorectal | 81-NOV-03 | C | 82-MAY-31 |
20 |
| I2L | AT-125; NSCLC | 81-NOV-03 | C | 84-MAR-09 |
36 |
| I3 | Spirogerm; NHL | 83-FEB-09 | C | 84-MAY-14 |
18 |
| I4 | Lonidamine; renal | 82-APR-01 | C | 84-MAY-05 |
33 |
| I4B | Lonidamine; breast | 83-OCT-01 | C | 85-MAY-13 |
42 |
| I5 | Spirogerm; melanoma | 83-JUN-01 | C | 84-MAY-14 |
25 |
| I6 | Interferon; renal | 83-NOV-01 | C | 84-SEP-20 |
44 |
| I7 | Mitoxantrone; mesothelioma | 83-JUL-12 | C | 85-FEB-15 |
24 |
| I8 | NMF; colorectal | 84-DEC-14 | C | 85-APR-29 |
12 |
| I9 | TCAR; colorectal | 85-MAY-01 | C | 86-MAR-05 |
21 |
| I10 | TCAR; breast | | W | |
|
| I11 | TCAR; NSCLC | 85-MAY-01 | C | 87-MAR-01 |
16 |
| I12 | CBDCA; ovarian | 84-AUG-01 | C | 85-FEB-21 |
53 |
| I13 | NMF; glioma | 84-DEC-01 | C | 85-APR-29 |
3 |
| I14 | NMF; melanoma | 84-DEC-01 | C | 85-APR-29 |
12 |
| I15 | Mitoxantrone; sarcoma | 84-AUG-03 | C | 85-DEC-09 |
27 |
| I16 | AT-125; NHL | 84-NOV-12 | C | 87-OCT-30 |
13 |
| I17 | Acivicin/cisplatin; NSCLC | 85-MAR-01 | C | 88-APR-25 |
17 |
| I18 | Flutamide; breast | 85-MAR-27 | C | 86-MAR-01 |
35 |
| I19 | Menogaril; breast | 85-MAY-30 | C | 86-MAR-15 |
25 |
| I20 | Menogaril; lymphoma | 85-MAY-30 | C | 88-NOV-14 |
27 |
| I21 | Menogaril; melanoma | 85-MAY-30 | C | 86-MAR-15 |
21 |
| I22 | 2' DCF; HC leukemia | 85-APR-26 | C | 86-JUL-15 |
31 |
| I23 | Acivicin; colorectal | 85-SEP-17 | C | 86-APR-28 |
27 |
| I24 | 2' DCF; renal | 85-SEP-06 | C | 86-NOV-26 |
20 |
| I25 | Trimetrexate; ovarian | 86-JUL-28 | C | 88-MAY-02 |
18 |
| I26 | Trimetrexate; melanoma | 86-JUL-28 | C | 87-NOV-06 |
19 |
| I27 | Trimetrexate; glioma | 86-JUL-28 | C | 88-MAR-14 |
15 |
| I28 | Trimetrexate; sarcoma | 86-JUL-28 | C | 87-DEC-31 |
28 |
| I28A | Trimetrexate; sarcoma | 88-JAN-25 | C | 89-JAN-09 |
27 |
| I29 | Adriamycin/Ifosfamide/DTIC; sarcoma | 86-JAN-21 | C | 87-NOV-03 |
43 |
| I30 | VP-16+DDP; mesothelioma | 86-JAN-09 | C | 87-APR-01 |
30 |
| I31 | VP-16+CBDCA; SCLC | 85-DEC-18 | C | 86-OCT-09 |
37 |
| I32 | Trimetrexate; phase I | 85-APR-01 | C | 85-DEC-01 |
15 |
| I33 | Epirubicin; SCLC | 86-APR-29 | C | 87-JUL-31 |
41 |
| I34 | IFN levamisole; melanoma; phase I | 86-NOV-13 | C | 87-MAY-07 |
10 |
| I35 | Lonidamine; breast | 86-DEC-08 | C | 88-JAN-08 |
4 |
| I36 | Didemnin-B; phase I | 86-NOV-01 | C | 91-NOV-29 |
53 |
| I37 | Flavone acetic acid; melanoma | | W | |
|
| I38 | TNF; renal | 88-JUN-01 | C | 89-SEP-01 |
26 |
| I39 | TNF; melanoma | | W | |
|
| I40 | TNF; colorectal | | W | |
|
| I41 | Hexamethylmelamine; SCLC | | W | |
|
| I42 | IV amonafide; SCLC | 87-OCT-23 | C | 88-APR-25 |
13 |
| I43 | DUP-937; phase I | 88-AUG-19 | C | 90-AUG-10 |
32 |
| I44 | DUP-937; phase I | 88-AUG-18 | C | 91-MAR-11 |
33 |
| I45 | Menogaril; breast | 89-AUG-27 | C | 90-APR-15 |
53 |
| I46 | Sulofenur; renal | 89-OCT-25 | C | 90-MAY-11 |
19 |
| I47 | Sulofenur; SCLC | 89-OCT-25 | C | 90-NOV-30 |
12 |
| I48 | PCV-3; oligodendroglioma | 89-FEB-06 | C | 92-SEP-02 |
33 |
| I49 | Gemcitabine; renal | 90-MAR-19 | C | 90-NOV-30 |
18 |
| I50 | Gemcitabine; SCLC | 91-FEB-04 | C | 92-SEP-29 |
29 |
| I51 | GMCSF+Carboplatin; ovarian; phase I | 89-MAY-29 | C | 90-FEB-10 |
15 |
| I51A | GMCSF+Carboplatin; ovarian; phase I | 90-FEB-10 | C | 90-SEP-28 |
7 |
| I52 | GM-CSF; SCLC; phase I | 89-NOV-06 | C | 90-SEP-19 |
6 |
| I53 | Anagrelide; thrombocythemia | | W | |
|
| I54 | Tiazofurin; glioma | 90-APR-18 | C | 91-MAY-28 |
18 |
| I55 | 10-EDAM; sarcoma | 90-SEP-04 | C | 92-MAR-06 |
32 |
| I56 | DUP-937; melanoma | 91-MAR-07 | C | 92-APR-23 |
16 |
| I57 | DUP-937; NSCLC | 91-APR-04 | C | 92-APR-02 |
16 |
| I58 | DUP-937; colorectal | 91-APR-04 | C | 91-NOV-10 |
17 |
| I59 | IL-3+Carboplatin; phase I | 90-DEC-10 | C | 92-MAR-27 |
17 |
| I60 | 10-EDAM; breast | 90-OCT-29 | C | 91-SEP-17 |
35 |
| I61 | 10-EDAM; melanoma | 91-JAN-08 | C | 92-JAN-21 |
16 |
| I62 | IL-2+IFN alpha; myeloma | 91-OCT-07 | C | 93-FEB-17 |
17 |
| I63 | Vinorelbine; renal | | W | |
|
| I64 | Vinorelbine; melanoma | | W | |
|
| I65 | Elsamitrucin; NSCLC | 92-JUN-01 | C | 92-DEC-04 |
17 |
| I66 | 13 cis-retinoic/IFN alpha; NSCLC | 92-JUN-15 | C | 93-MAY-28 |
34 |
| I67 | Fostriecin; phase I | 92-SEP-10 | C | 96-MAY-21 |
46 |
| I68 | Taxotere; breast | 92-JUN-01 | C | 93-JUN-30 |
51 |
| I69 | Taxotere; SCLC | 93-FEB-08 | C | 93-OCT-18 |
14 |
| I70 | Taxotere; renal | 92-AUG-24 | C | 93-FEB-03 |
20 |
| I71 | Topotecan; sarcoma | 92-JUN-08 | C | 94-FEB-04 |
32 |
| I72 | Sandostatin; colorectal | | W | |
|
| I73 | Mifepristone; breast | 92-APR-27 | C | 95-FEB-28 |
28 |
| I74 | Cisplatin/Taxol; ovarian; phase I | 92-NOV-02 | C | 94-OCT-07 |
29 |
| I75 | Topotecan; glioma | 92-SEP-08 | C | 94-JAN-25 |
31 |
| I76 | Taxotere; glioma | 94-APR-04 | C | 95-APR-28 |
18 |
| I77 | Taxotere; sarcoma | 94-MAR-28 | C | 95-JUN-30 |
32 |
| I78 | Didemnin B; lymphoma | 93-SEP-01 | C | 94-OCT-25 |
10 |
| I79 | Taxol/Ifosfamide; NSCLC; phase I | 93-SEP-13 | C | 96-FEB-08 |
68 |
| I80 | Taxol/radiation; NSCLC; phase I | 94-MAR-14 | C | 96-JUN-14 |
17 |
| I81 | Tallimustine; SCLC | 94-AUG-16 | C | 95-JUN-14 |
16 |
| I82 | Topotecan; ovarian; rand. phase II | 94-JUL-08 | C | 97-APR-22 |
104 |
| I83 | Arotinoid+Tamoxifen; breast | | W | |
|
| I84 | Topotecan+VP16; relapsed AML; phase I | 94-DEC-07 | C | 95-NOV-23 |
11 |
| I85 | JM216/oral VP16; phase I | 94-AUG-22 | C | 94-NOV-08 |
6 |
| I86 | 9-aminocamptothecin CD; phase I | 95-FEB-13 | C | 96-OCT-28 |
20 |
| I87 | High dose levamisole; melanoma; phase Ib | 95-JUN-26 | C | 97-MAY-01 |
28 |
| I88 | 9-cis-retinoic acid/INF alpha; renal; phase I/II | 95-AUG-03 | C | 97-APR-29 |
38 |
| I89 | LY231514; NSCLC | 95-SEP-12 | C | 97-FEB-04 |
33 |
| I90 | LY231514; colorectal | 95-SEP-12 | C | 96-JUN-21 |
33 |
| I91 | BB2516; melanoma | 95-AUG-01 | C | 97-MAR-31 |
29 |
| I92 | 9-aminocamptothecin;14 day cont. inf. q28d;phaseI | | W | |
|
| I93 | Amifostine/Paclitaxel; breast; randomized | 96-APR-24 | C | 98-SEP-24 |
50 |
| I94 | Gemcitabine; malignant glioma | 96-MAY-06 | C | 97-APR-28 |
20 |
| I95 | Gemcitabine/Cisplatin; bladder | 96-AUG-06 | C | 97-OCT-03 |
33 |
| I96 | JM216+VP16; phase I | 96-JUL-15 | C | 99-JUN-03 |
33 |
| I97 | DPPE/Adriamycin; breast | 96-MAY-10 | C | 98-JAN-06 |
42 |
| I98 | Tomudex/Doxorubicin; gastric; phase I | 96-OCT-24 | C | 99-APR-07 |
25 |
| I99 | Topotecan; lymphoma | | W | |
|
| I100 | Topotecan & etoposide; AML | 96-OCT-09 | C | 98-MAY-13 |
26 |
| I101 | RPR 109881A; phase I | 96-SEP-23 | C | 98-MAR-13 |
29 |
| I102 | JM216; cervix | 97-JAN-27 | C | 99-FEB-16 |
18 |
| I103 | BCH4556; phase I | 97-JAN-27 | C | 99-MAR-02 |
45 |
| I104 | Bryostatin 1; melanoma (rand. phase II) | 97-JUN-05 | C | 98-OCT-26 |
34 |
| I105 | 776C85 + 5FU; head & neck | 97-FEB-10 | C | 99-FEB-22 |
32 |
| I106 | Topotecan/cisplatin/paclitaxel; ovarian | 97-JUN-10 | C | 98-MAY-07 |
44 |
| I107 | BAY 12-9566; phase I | 97-JAN-27 | C | 97-DEC-10 |
29 |
| I106B | Topotecan/cisplatin/paclitaxel/carboplatin;ovarian | 99-APR-27 | C | 99-DEC-16 |
13 |
| I108 | Topotecan & etoposide; non-Hodgkin's lymphoma | 97-JUN-05 | C | 98-MAY-07 |
23 |
| I109 | Topotecan; oligodendroglioma | 97-DEC-08 | C | 00-APR-20 |
17 |
| I110 | LY231514/CDDP; NSCLC | 98-APR-15 | C | 99-JUN-07 |
32 |
| I111 | 3521/5132; prostate; rand. phase II | 98-FEB-12 | C | 99-JAN-22 |
31 |
| I112 | 3521/5132; colorectal; rand. phase II | 98-MAR-11 | C | 99-SEP-29 |
38 |
| I113 | BAY 12-9566/5FU/Doxorubicin; phase I | 98-FEB-10 | C | 99-SEP-20 |
31 |
| I114 | SR49059; SCLC | 99-APR-05 | C | 00-OCT-20 |
7 |
| I115 | Aplidine; phase I | 99-FEB-15 | C | 02-FEB-07 |
37 |
| I116 | 5132; ovary | 99-FEB-01 | C | 00-MAY-05 |
22 |
| I117 | ET 743; renal | | W | |
|
| I118 | ET 743; ovary | | W | |
|
| I119 | BCH 4556; renal | 99-JUN-16 | C | 00-MAR-21 |
35 |
| I120 | BCH 4556; NSCLC | 99-JUN-16 | C | 00-MAY-30 |
18 |
| I121 | LY335979 + vinorelbine; phase I | 99-MAR-01 | C | 00-NOV-06 |
21 |
| I122 | ZD 1839; phase I | 99-JUN-14 | C | 01-JUN-28 |
56 |
| I123 | NX-211; phase I | 99-FEB-25 | C | 00-JUN-09 |
37 |
| I124 | MG-98; 21 day infusion; phase I | 99-FEB-11 | C | 00-MAY-12 |
14 |
| I125 | MG-98; twice weekly; phase I | 99-FEB-22 | C | 01-MAR-08 |
19 |
| I126 | Letrozole endometrium | 00-JAN-19 | C | 01-MAY-16 |
33 |
| I127 | Flavopiridol; mantle cell lymphoma | 00-JAN-24 | C | 01-OCT-10 |
33 |
| I128 | SCH66336; bladder | 99-DEC-03 | C | 01-MAY-01 |
20 |
| I129 | ZD0473; breast | 00-JAN-14 | C | 01-MAR-02 |
33 |
| I130 | T900607; phase I | 00-APR-07 | C | 02-DEC-19 |
30 |
| I131 | ZD0473 & docetaxel; phase I | 00-MAY-04 | C | 02-FEB-08 |
33 |
| I132 | Temozolomide; breast | 00-AUG-01 | C | 01-SEP-26 |
19 |
| I133 | NX211 & cisplatin; phase I | 00-MAR-22 | C | 01-NOV-22 |
14 |
| I133B | NX211 & cisplatin; phase I | | W | |
|
| I134 | BAY 38-3441; phase I | 00-MAY-12 | C | 03-JAN-16 |
34 |
| I135 | COT; phase I | 00-JUN-28 | C | 02-FEB-07 |
31 |
| I136 | Flavopiridol; sarcoma | 00-JUL-04 | C | 01-MAR-06 |
18 |
| I137 | Flavopiridol; melanoma | 00-JUL-04 | C | 01-JUL-13 |
17 |
| I138 | NX211; ovary; rand. phase II | 00-OCT-31 | C | 01-SEP-21 |
81 |
| I139 | T138067; glioma | 00-NOV-08 | C | 02-JAN-09 |
19 |
| I140 | ZD1839; prostate; rand. phase II | 01-APR-24 | C | 02-APR-25 |
40 |
| I141 | BAY 43-9006;myelodysplasia & leuk; rand.phase I | 01-OCT-01 | C | 04-APR-01 |
42 |
| I142 | SarCNU; glioma | 02-JAN-10 | C | 02-DEC-17 |
10 |
| I143 | MG98; renal cell carcinoma | 01-MAY-01 | C | 02-MAY-10 |
19 |
| I144 | LY293111; phase I | 01-MAR-23 | C | 04-JUN-29 |
29 |
| I145 | ZD6474; multiple myeloma | 02-OCT-02 | C | 04-APR-08 |
18 |
| I146 | SarCNU; colorectal | 01-OCT-30 | C | 03-AUG-14 |
18 |
| I147 | OSI-7836; phase I | 01-SEP-28 | C | 04-FEB-17 |
27 |
| I148 | OSI-774; endometrium | 02-JAN-10 | C | 04-MAR-16 |
34 |
| I149 | OSI-774 & carboplatin; ovary | 02-JAN-10 | C | 04-JUN-01 |
50 |
| I150 | PS341; mantle cell lymphoma | 02-JUL-04 | C | 04-JUL-28 |
30 |
| I151 | LY317615 & carbo/taxol; phase I | | W | |
|
| I152 | PS341; Waldenstrom's Macroglobulinemia | 02-AUG-27 | C | 05-MAR-23 |
27 |
| I153 | OGX; prostate; phase I | 02-DEC-06 | C | 04-MAY-05 |
25 |
| I154 | OGX + docetaxel; phase I | 03-MAR-06 | C | 05-JUN-28 |
40 |
| I155 | perifosine; sarcoma | 03-MAY-15 | C | 04-AUG-10 |
17 |
| I156 | perifosine; melanoma | 03-MAY-16 | C | 04-APR-26 |
18 |
| I157 | OSI-774 & cisplatin, head and neck | 03-FEB-10 | C | 04-SEP-22 |
14 |
| I158 | ALVAC; melanoma; phase I | | W | |
|
| I159 | ALVAC; melanoma | | W | |
|
| I160 | CCI-779; endometrium | 04-JAN-14 | C | 07-JUN-15 |
62 |
| I161 | Triapine; RCC | 04-JAN-16 | C | 05-APR-05 |
19 |
| I162 | RAD001C; glioma; phase I | 06-JUL-25 | C | 09-JUN-01 |
32 |
| I163 | RAD001C; breast | 05-JAN-19 | C | 07-JAN-11 |
49 |
| I164 | OGX-011 & docetaxel, advanced breast | 05-JUN-27 | C | 06-SEP-29 |
15 |
| I165 | OGX-011 & docetaxel, prostate | 05-JUN-27 | C | 06-DEC-21 |
82 |
| I166 | AEG35156 & docetaxel; phase I | 05-APR-04 | C | 06-JUL-10 |
10 |
| I166B | AEG35156 & docetaxel; phase I | 06-JUN-20 | C | 08-MAR-20 |
27 |
| I167 | BAY 43-9006; prostate | 04-JUN-21 | C | 05-DEC-20 |
28 |
| I168 | SB-715992; hepatocellular carcinoma | 04-NOV-24 | C | 06-MAY-04 |
15 |
| I169 | SB-715992; malignant melanoma | 04-NOV-22 | C | 06-MAY-01 |
17 |
| I170 | GW572016; malignant glioma; phase I/II | 04-DEC-16 | C | 07-MAY-08 |
24 |
| I171 | AZD2171; NSCLC or colorectal; phase I | 05-JAN-13 | C | 09-FEB-17 |
50 |
| I172 | Bortezomib & gemcitabine; mantle cell lymphoma | 06-JUN-14 | C | 08-SEP-19 |
29 |
| I173 | AZD5030 & gemcitabine; pancreatic; phase I/II | 05-JUL-19 | C | 08-MAY-29 |
34 |
| I174 | BMS-275183; NSCLC | | W | |
|
| I175 | AZD2171; advanced NSCLC or colorectal cancer; phase I | 05-AUG-08 | C | 07-MAR-30 |
31 |
| I176 | GeminX; SCLC | | W | |
|
| I177 | AT7519M; phase I | 06-AUG-22 | C | 11-APR-04 |
34 |
| I178 | JX-963 plus GM-CSF; solid tumours; phase I | | C | 11-APR-29 |
|
| I179 | CCI-779 with carboplatin & paclitaxel; phase I | 06-OCT-25 | C | 09-MAR-27 |
39 |
| I180 | AMG-706, cisplatin & etoposide; NSCLC; phase I/II | | W | |
|
| I181 | AT9283; advanced incurable malignancy; phase I | 07-JAN-04 | C | 09-NOV-24 |
35 |
| I182 | Sunitinib (SU11248); large B-cell lymphoma | 06-NOV-08 | C | 09-MAR-24 |
19 |
| I183 | Sunitinib (SU11248); pleural mesothelioma | 06-NOV-10 | C | 10-SEP-10 |
39 |
| I184 | Sunitinib (SU11248); cervical carcinoma | 06-NOV-09 | C | 08-MAY-12 |
19 |
| I185 | Sunitinib (SU11248); ovarian, fallopian tube | 06-NOV-10 | C | 08-APR-17 |
31 |
| I186 | BAY 43-9006 & cytarabine; AML/high risk MDS; phase I/II | 07-JUL-24 | C | 09-DEC-10 |
21 |
| I187 | AZD2281 & irinotecan; colorectal; phase I | 07-AUG-13 | H | |
|
| I188 | SB939; advanced cancer; phase I | 07-JUN-21 | C | 10-MAR-16 |
39 |
| I189 | rIL-21; metastatic or recurrent melanoma | 07-JUL-10 | C | 09-AUG-17 |
40 |
| I190 | MK-0646 IGFR; small cell lung; phase I/II | 09-JAN-30 | C | 11-MAR-10 |
12 |
| I191 | AKI AT 9283; multiple myeloma | 10-JUN-15 | O | |
|
| I192 | Deforolimus; endometrial | 08-AUG-26 | C | 10-AUG-11 |
35 |
| I193 | AT7519M; Lymphocytic; phase II | | P | |
|
| I194 | AT7519M; Lymphoma; phase II | | P | |
|
| I195 | SB939; Prostate; phase II | 10-FEB-10 | C | 11-NOV-04 |
32 |
| I196 | GSK1363089+erlotinib; NSCLC; phase I/II | 09-DEC-17 | H | |
|
| I197 | GSK1363089; Breast; phase II | 10-MAY-25 | O | |
|
| I198 | GSK1363089 and trastuzumab/lapatinib; Breast; phase I/II | 10-JUN-03 | H | |
|
| I199 | CCI779; Cervix; phase II | 09-DEC-17 | C | 11-OCT-27 |
38 |
| I200 | SB393; Sarcoma; phase II | 10-MAR-18 | C | 12-JAN-25 |
24 |
| I201 | 43162 | | W | |
|
| I202 | IL21; Melanoma; phase II | 10-JUN-28 | O | |
|
| I203 | SB939; Pediatric; phase I | 10-SEP-21 | C | 12-JAN-25 |
12 |
| I204 | PX-866; Glioma; phase II | 10-DEC-09 | H | |
|
| I205 | PX-866; CRPC; phase II | 11-APR-04 | O | |
|
| I206 | Sunitinib/Temsirolimus; Rare tumors; phase II | 11-JUL-14 | O | |
|
| I207 | PF-03446962; Mesothelioma; phase II | 11-NOV-30 | O | |
|
| I208 | BKM120 + Panitumumab; Colorectal Cancer; phase I/II | | P | |
|
| I209 | | | P | |
|
